Metastatic colorectal cancer patients with KRAS mutated tumors and high plasma TIMP-1 level seems to benefit from EGFR-inhibition therapy: results from the NORDIC VII Study
- Tarpgaard, L. S. (Foredragsholder)
Aktivitet: Foredrag og mundtlige bidrag › Foredrag og præsentationer i privat eller offentlig virksomhed